Notice
A combined laser microdissection and mass spectrometry method for proteomic analysis of tissue sections for the indentification of tumor signatures
- document 1 document 2 document 3
- niveau 1 niveau 2 niveau 3
Descriptif
Clinical and biological samples : opportunities and challenges for translational research
A challenge in oncology is to better define thetumor of the patient to study the pathology and of course to find and to usethe right treatment. Genetic and transcriptomic analyses allow a cancerclassification, and give a lot of informations concerning carcinogenesis.However, the proteomic analysis can complete the genomic analysis and precisethe tumor features.
With the Frederic Saltel’s group within theINSERM 1053 Unit of Bordeaux, we have already developed a new method ofproteomic analysis of subcellular compartments after laser microdissection thathas been the object of a patent registration. Resulting from a know-howacquired during the development of this new method, we have developed aprocedure combining laser microdissection and mass spectrometry analysis toidentify and compare the levels of protein expression between two tissuespieces of formalin fixed paraffin embedded tissue sections. Our approachpresents the principal advantage to be compatible with biopsy, the currentbiological material available for clinical assays. Moreover, with this approachwe will obtain quantitative data in comparison with classicalimmunohistochemistry.
Our subject of study in the laboratory is thehepatocellular carcinoma (HCC), the sixth most prevalent cancer and the thirdmost frequent cause of cancer-related death. We already validated our protocolon two cases of HCC and one low-grade dysplastic nodule, one of the earlierstages of liver carcinogenesis. Now, we want to enlarge our analyses on abigger cohort to compare the proteome of the different stages of livercarcinogenesis. We will use the proteomic data to generate proteomic signaturesof each stage of liver carcinogenesis and validate the signatures generated.Finally we will propose a new tool for tumor characterization and biomarkersquantification that can be applicable in clinic.
Cette présentation a été donnée dans le cadre du BRIO SIRICscientific day 3 organisé annuellement par le SIRIC BRIO et qui a pour but deréunir tous les acteurs du SIRIC BRIO et plus largement de la cancérologie àBordeaux.
Thème
Dans la même collection
-
Flash talk - Call for proposal FAC 2014
ElustondoFrédéricWodrichHaraldFaustinBenjaminSaltelFrédéricCognetLaurentPersonalized breast cancer therapy based on viral functional assays to score pathway activity Harald Wodrich, University of Bordeaux State-of-the-art mass sequencing technology has paved the road
-
Experts panel discussion: What opportunities and best practices for the use of clinical material in…
CameronDavidEn point d'orgue du Scientific BRIO Day, David Cameron, spécialiste reconnu en Oncologie, Professeur à l'Université d'Edimbourg, anime un débat sur la question des opportinités et bonnes pratiques
-
A new weapon against the tobacco industry : class action lawsuit using a novel epidemiologic param…
SiemiatyckiJackEpidemiology and public health Lawsuits against the tobacco industry, if successful, have the potential to compensate victims of smoking and to diminish the capacity of the tobacco industry to
-
-
Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas
Le Guyader-PeyrouSandraEpidemiology and public health The principal aim of this thesis will describe the care pathway of diffuse large B cell lymphoma (DBCL) and follicular lymphoma (FL) in the general population and
-
-
BRIO strategic challenges and the implementation of a translational culture in Bordeaux
SoubeyranPierreAbout BRIO Siric challenges and actions BRIO’s strategic objective is to strengthen Bordeaux’s leadership in Cancer Research through the creation of a dynamic cancer research community, the
-
How studying hematological malignancies subtypes may inform epidemiologic and clinical research
MonnereauAlainEpidemiology and public health The aim of the talk entitled "How studying hematological malignancies (HM) subtypes may inform epidemiologic and clinical research" is to bring to the audience
-
BRIO supporting action to integrated cancer research in Bordeaux
MeoniPaoloAbout BRIO Siric challenges and actions The success of BRIO’s approach and the realization of its potential impact on the translational research community in Bordeaux rely both on the efficient
-
Modelling prognostic capabilities of tumor size : application to colorectal cancer
RondeauVirginieEpidemiology and public health In oncology, the international WHO and RECIST criteria have allowed the standardization of tumor response evaluation in order to identify the time of disease
-
Sarcoma Database: a unique tool for research on mesenchymal tumors
CoindreJean-MichelClinical biology session The main sarcoma databases are the Conticabase (https://conticabase.sarcomabcb.org) and the ConticaGist (https://conticagist.sarcomabcb.org) with 18000 patients and which
Sur le même thème
-
Place du brevet dans la recherche d'un laboratoire
DutreixMarieGirardPierre-MarieInterview : la place du brevet dans la recherche d'un laboratoire par Marie Dutreix, directrice de recherche à l'institut Curie.
-
Influence des comportements de santé sur le jugement des femmes consommatrices et atteintes de canc…
AuriolCamilleLes doctorants des universités de Toulouse (UT1C/UT2J/UT3) et de l'Université de Québec à Montréal (UQAM) ont organisé un séminaire de présentation et d'échanges autour de leurs travaux de recherche,
-
[FAB.ISS] Session #5 La fabrique des inégalités sociales de santé et cancer(s)
NicaiseSarahMayèreAnneTerralPhilippeGaboritEmilieDefossezAdrienBartheJean-FrançoisSymposium International FAB.ISS - Ce symposium proposé en 2020 en visioconférence s'intéresse à la fabrique des inégalités sociales de santé, du point de vue des disciplines de sciences humaines et
-
Explorer les impensés de dispositifs de télé-surveillance sur les patient.e.s et leurs modes de vie
MayèreAnneLa conférence du Pr. Anne Mayère (CERTOP, IFERISS, Université de Toulouse, France) est organisée dans le cadre du séminaire télésanté de la Chaire de recherche en francophonie internationale sur les
-
Les jeudis du Grhapes : « Approches sociologiques de l'inclusion », Claude-Julie Bourque, sociolog…
« Approches sociologiques de l'inclusion » Guérir, et puis après... ? Claude-Julie Bourque, sociologue, professeure-chercheure adjointe au département de pédiatrie de la Faculté de médecine de
-
SFjRO Rouen 2019 - Radiosensibilité et apoptose lymphocytaire
Radiosensibilité et apoptose lymphocytaire
-
SFjRO Rouen 2019 - Applications cliniques de la protons thérapie
Applications cliniques de la protons thérapie
-
SFjRO Rouen 2019 - Association therapie systémique et radiothérapie
Association therapie systémique et radiothérapie
-
SFjRO Rouen 2019 - Bases physiques et biologie de la proton thérapie
Bases physiques et biologie de la proton thérapie
-
SFjRO Montpellier 2019 - Radio-hormonothérapie
SFjRO Montpellier 2019 - Radio-hormonothérapie
-
-
SFjRO Montpellier 2019 - Hypofractionnement
SFjRO Montpellier 2019 - Hypofractionnement